undamentalytics Newsletter
Sign in

Tscan Therapeutics, Inc. income statement

In fiscal 2025, Tscan Therapeutics, Inc. reported revenue of $10.3m, up 266.7% on the year before, operating income of −$136m (a -1315.4% margin) and net income of −$130m, or −$1.00 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11014213107
Research and development2145608810711497
General and administrative7142026303231
Operating income−26−49−67−93−135−136−121
Interest expense——14433
Income tax—————0—
Net income−26−49−66−89−127−130−118
Diluted EPS−$14.26−$2.08−$2.75−$1.36−$1.14−$1.00−$0.91
Diluted shares (average)2m23m24m66m112m130m130m
EBITDA−25−45−62−88−131−133−118

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EVAX vs TCRXROIV vs TCRXHCWB vs TCRXFATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tscan Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tscan Therapeutics, Inc.